Avastin’s Breast Cancer Approval Followed CDER Rift On Efficacy

The Center for Drug Evaluation and Research is expected to present a united front supporting withdrawal of Avastin’s (bevacizumab) metastatic breast cancer claim at a June 28-29 hearing.